Table 1. HCV inhibitors targeting different steps of the HCV entry process. Inhibitors in bold are in clinical trials.

Entry step	Compound	Target/Mechanism	References
Primary binding	Heparin-like molecules	HCV-HSPG interaction	[6, 7, 8, 53]
	Epigallocatechin gallate	HCV-HSPG interaction	[54–56]
	Tannic acid	Docking of HCV at cell surface	[57]
	Gallic acid	Docking of HCV at cell surface	[58]
	Delphinidin	Docking of HCV at cell surface	[59]
Specific binding	281816	HCV E2-CD81 interaction	[60]
	Oleanane-type triterpenes	HCV E2-CD81 interaction	[61]
	Saikosaponin b2	HCV E2-CD81 interaction	[62]
	Anti-CD81 antibody	HCV E2-CD81 interaction	[63]
	Anti-SRBI antibody	HCV-SRBI interaction	[64, 65]
	Anti-ApoE antibody	HCV-associated ApoE-HSPG interaction	[5]
	Neutralizing antibodies	HCV E1/E2	[66–68]
	Polyclonal anti-HCV IgG	HCV E1/E2	[69, 70]
	ApoE-derived peptide	HCV-associated ApoE-HSPG interaction	[71]
Post-binding	Anti-CLDN1 antibodies	CD81-CLDN1 coreceptor complex	[48, 72–75]
	CLDN1-derived peptide	CD81-CLDN1 coreceptor complex	[76]
	Erlotinib	CD81-CLDN1 coreceptor complex; signaling	[23]
	ITX5061	SRBI lipid transfer activity	[77]
Internalization	Arbidol	HCV endosomal trafficking	[78]
	Silibinin	HCV endosomal trafficking	[79]
Fusion	Flunarizine	HCV genotype 2 fusion (E1 and/or E2)	[38]
	Ferroquine	HCV fusion (E1)	[81]
	RAFIs	HCV envelope curvature	[85, 86]
	Phenothiazines	HCV envelope fluidity	[87]
	Benzhydrylpiperazines	HCV envelope fluidity	[88]
	Curcumin	HCV envelope fluidity	[89]
	Polyunsaturated liposomes	Cellular membrane (cholesterol depletion)	[90]
	Statins	Cellular membrane (cholesterol depletion)	[91]
	Ezetimibe	Cellular membrane (cholesterol depletion)	[30]
	Photosensitizers (LJ001)	Lipid oxidation (viral envelope)	92, 93]